AbbVie
ABBV
$169.54
Share price
0.98%
Change (1 day)
3.33%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Revenue for AbbVie (ABBV)
Revenue in 2023 (TTM): $54.31 B
According to AbbVie's latest financial reports the company's current revenue (TTM) is $54.31 B. In 2022 the company made a revenue of $58.05 B an increase over the years 2021 revenue that were of $56.19 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie from 2011 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $54.31 B | -6.44% |
| 2022 | $58.05 B | 3.3% |
| 2021 | $56.19 B | 22.69% |
| 2020 | $45.80 B | 37.69% |
| 2019 | $33.26 B | 1.57% |
| 2018 | $32.75 B | 16.08% |
| 2017 | $28.21 B | 10.06% |
| 2016 | $25.63 B | 12.16% |
| 2015 | $22.85 B | 14.52% |
| 2014 | $19.96 B | 6.23% |
| 2013 | $18.79 B | 2.23% |
| 2012 | $18.37 B | 5.36% |
| 2011 | $17.44 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $58.49 B | 7.69% | 🇺🇸 USA |
 Eli Lilly LLY | $34.12 B | -37.18% | 🇺🇸 USA |
 Amgen AMGN | $28.19 B | -48.10% | 🇺🇸 USA |
 Biogen BIIB | $9.83 B | -81.89% | 🇺🇸 USA |
 Gilead Sciences GILD | $27.11 B | -50.08% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $45.00 B | -17.14% | 🇺🇸 USA |
 AstraZeneca AZN | $45.81 B | -15.66% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $37.84 B | -30.32% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $1.88 B | -96.53% | 🇺🇸 USA |